A pre-specified interim analysis concluded with a favorable recommendation to continue the LUNAR study DMC stated that building 534 patients is probably unnecessary and may be unethical for patients randomized.
STATUE: Neural network framework. vision more Credit: Smedley, Aberle and Hsu, doi 10.1117 / 1.JMI.8.3.031906. Despite our remarkable advances in medicine and healthcare, the cure for cancer continues to elude.
SHANGHAI and HONG KONG, May 12, 2021 / PRNewswire / - Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing world-class premium.
An EMD Serono drug designed to treat lung cancer powered by a rare genetic alteration is now approved by the FDA, which is joining a growing list of targeted cancer.
A leading treatment that cuts the risk of lung problems in half cancer patients who have recurrence of the disease after undergoing treatment is being rolled out by NHS England.In.
Just weeks after a late-stage candidate saw a wall hit in a non-small cell lung cancer (NSCLC) subtype, Merck KGaA's EMD Serono has received accelerated FDA approval for another major.